{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T19:36:37Z","timestamp":1791488197491,"version":"4.3.4"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T00:00:00Z","timestamp":1762819200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T00:00:00Z","timestamp":1762819200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Malar J"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    <jats:italic>Plasmodium vivax<\/jats:italic>\n                    remains the predominant cause of malaria in Pakistan, accounting for approximately 85% of confirmed cases. The recurrent nature of\n                    <jats:italic>P. vivax<\/jats:italic>\n                    , driven by dormant liver-stage hypnozoites, poses a major obstacle to malaria control. Pakistan currently uses a 14-day low-dose primaquine regimen (3.5\u00a0mg\/kg total dose) without routine G6PD testing, a strategy limited by poor adherence and suboptimal efficacy. In 2024, the World Health Organization (WHO) recommended high-dose primaquine (7\u00a0mg\/kg) or single-dose tafenoquine (300\u00a0mg) as more effective alternatives, but evidence on their programmatic implementation remains limited. The EFFORT clinical trial evaluated the safety and effectiveness of 7-day-high-dose primaquine and single-dose tafenoquine compared to the standard 14-day-low-dose regimen. Conducted across four endemic countries, including Pakistan, the trial found both regimens to be well tolerated and effective in preventing relapse. In Pakistan, the added benefit of high-dose primaquine over the standard regimen was modest but consistent with findings from other South Asian countries. The findings of EFFORT highlight significant benefits of tafenoquine in\n                    <jats:italic>P. vivax<\/jats:italic>\n                    endemic settings beyond those currently endorsed in the 2024 WHO guidelines. A national dissemination meeting was held at the Aga Khan University hospital Karachi on 10th April 2025 organized by Aga Khan University and Menzies School of Health Research. The meeting brought together national and provincial stakeholders to review study results and explore implications for radical cure policy and implementation in Pakistan. Key themes included policy alignment, phased implementation of tafenoquine and G6PD testing, planning and funding constraints, private sector engagement, and the importance of sustained dialogue between researchers and malaria program leaders.\n                  <\/jats:p>","DOI":"10.1186\/s12936-025-05636-8","type":"journal-article","created":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T15:20:56Z","timestamp":1762874456000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Effectiveness of tafenoquine and primaquine for radical cure of Plasmodium vivax: a meeting report from dissemination of results of the EFFORT trial to stakeholders in Pakistan"],"prefix":"10.1186","volume":"24","author":[{"given":"Bushra","family":"Qurashi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shan-e-Zehra","family":"Zaidi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad","family":"Mushtaque","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Faisal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeeshan","family":"Haroon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baseer","family":"Agha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naseer","family":"Hammal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdul","family":"Hameed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Raza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Umair","family":"Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asia","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fareeha Abdul","family":"Jabbar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zainab Rafeeq","family":"Adam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tariq","family":"Mehmood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ric N.","family":"Price","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Najia","family":"Ghanchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamala","family":"Thriemer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Asim","family":"Beg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,11]]},"reference":[{"key":"5636_CR1","unstructured":"WHO. World malaria report 2023. Geneva, World Health Organization, 2023."},{"key":"5636_CR2","unstructured":"Department of Malaria Control. Pakistan national strategic plan: malaria control and elimination 2021\u20132035. Islamabad, Pakistan, 2021. Available from: https:\/\/apmen.org\/sites\/default\/files\/all_resources\/Pakistan%20National%20Strategic%20plan%20%28NSP%20MCE%202021-2035%29.pdf."},{"key":"5636_CR3","unstructured":"WHO. Malaria\u2013Pakistan. Disease Outbreak News, 2022. Available from: https:\/\/www.who.int\/emergencies\/disease-outbreak-news\/item\/2022-DON413."},{"key":"5636_CR4","unstructured":"Asia Pacific Malaria Elimination Network (APMEN). Accelerating implementation of radical cure for P. vivax malaria in Pakistan. APMEN.org blog, 2025. Available from: https:\/\/apmen.org\/blog\/accelerating-malaria-elimination-pakistan-national-drive-powered-innovation-and-partnership."},{"key":"5636_CR5","first-page":"343","volume":"49","author":"NM Maheshwari","year":"2024","unstructured":"Maheshwari NM, Bashir A, Chand S, Ali A, Parkash O, Hingorjo B. Frequency of Glucose-6-Phosphate dehydrogenase deficiency in jaundiced neonates. Rawal Med J. 2024;49:343\u20136.","journal-title":"Rawal Med J"},{"key":"5636_CR6","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1002299","volume":"14","author":"T Abreha","year":"2017","unstructured":"Abreha T, Hwang J, Thriemer K, Tadesse Y, Girma S, Melaku Z, et al. Comparison of artemether-lumefantrine and chloroquine with and without primaquine for the treatment of Plasmodium vivax infection in Ethiopia: a randomized controlled trial. PLoS Med. 2017;14:e1002299.","journal-title":"PLoS Med"},{"key":"5636_CR7","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1186\/s12936-023-04725-w","volume":"22","author":"P Mehdipour","year":"2023","unstructured":"Mehdipour P, Rajasekhar M, Dini S, Zaloumis S, Abreha T, Adam I, et al. Effect of adherence to primaquine on the risk of Plasmodium vivax recurrence: a WorldWide Antimalarial Resistance Network systematic review and individual patient data meta-analysis. Malar J. 2023;22:306.","journal-title":"Malar J"},{"key":"5636_CR8","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/S1473-3099(23)00430-9","volume":"24","author":"RJ Commons","year":"2024","unstructured":"Commons RJ, Rajasekhar M, Edler P, Abreha T, Awab GR, Baird JK, et al. Effect of primaquine dose on the risk of recurrence in patients with uncomplicated Plasmodium vivax: a systematic review and individual patient data meta-analysis. Lancet Infect Dis. 2024;24:172\u201383.","journal-title":"Lancet Infect Dis"},{"key":"5636_CR9","unstructured":"WHO. Guidelines for malaria, 30 November 2024. Geneva, World Health Organization, 2024."},{"key":"5636_CR10","unstructured":"Medicines for Malaria Venture and GSK, First single\u2011dose medicine for P.\u202fvivax malaria prequalified by WHO and included in WHO guidelines. Press Release, 2024. Available from: https:\/\/www.gsk.com\/media\/k4blikb0\/press-release-first-single-dose-medicine-for-p-vivax-malaria-prequalified-by-who-and-included-in-who-guidelines.pdf."},{"key":"5636_CR11","doi-asserted-by":"crossref","unstructured":"Degaga TS, Pasaribu AP, Tripura R, Ghanchi N, Rajasekhar M, Adhikari B, et al. Effectiveness and safety of high dose primaquine and tafenoquine in Plasmodium vivax patients (EFFORT)-a multi-centre, open label, superiority randomised controlled trial. Lancet. 2025 (preprint).","DOI":"10.2139\/ssrn.5409116"},{"key":"5636_CR12","doi-asserted-by":"publisher","DOI":"10.1136\/bmjgh-2023-012675","volume":"8","author":"R Verma","year":"2023","unstructured":"Verma R, et al. Safety and efficacy of primaquine in patients with Plasmodium vivax malaria from South Asia: a systematic review and individual patient data meta-analysis. BMJ Glob Health. 2023;8:e012675.","journal-title":"BMJ Glob Health"},{"key":"5636_CR13","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1016\/S0140-6736(07)60160-3","volume":"369","author":"A Ratcliff","year":"2007","unstructured":"Ratcliff A, Siswantoro H, Kenangalem E, Maristela R, Wuwung RM, Laihad F, et al. Two fixed-dose artemisinin combinations for drug-resistant falciparum and vivax malaria in Papua, Indonesia: an open-label randomised comparison. Lancet. 2007;369:757\u201365.","journal-title":"Lancet"},{"key":"5636_CR14","unstructured":"WHO. Guidelines for malaria, 16 October 2023. Geneva, World Health Organization, 2023."},{"key":"5636_CR15","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1016\/S1473-3099(23)00213-X","volume":"23","author":"I Sutanto","year":"2023","unstructured":"Sutanto I, Soebandrio A, Ekawati LE, Chand K, Noviyanti R, Satyagraha AW, et al. Tafenoquine co-administered with dihydroartemisinin-piperaquine for the radical cure of Plasmodium vivax malaria (INSPECTOR): a randomised, placebo-controlled, efficacy and safety study. Lancet Infect Dis. 2023;23:1153\u201363.","journal-title":"Lancet Infect Dis"},{"key":"5636_CR16","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1186\/s12936-024-05209-1","volume":"23","author":"AP Santos","year":"2024","unstructured":"Santos AP, Brito M, Oliveira A, D\u00e1vila RN, Gama H, Silva E, et al. Assessing tafenoquine implementation in Brazil: a qualitative evaluation of perceptions of healthcare providers and Plasmodium vivax patients (QualiTRuST study). Malar J. 2024;23:399.","journal-title":"Malar J"},{"key":"5636_CR17","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/s12936-025-05295-9","volume":"24","author":"DB Pereira","year":"2025","unstructured":"Pereira DB, Lacerda MV, Bilkhu P, Duarte C, Fita IG, Jackson F, et al. An observational pilot study of an active surveillance tool to enhance pharmacovigilance in Brazil. Malar J. 2025;24:71.","journal-title":"Malar J"},{"key":"5636_CR18","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0012197","volume":"18","author":"A Santos","year":"2024","unstructured":"Santos A, Brito M, Silva E, Rocha F, Oliveira A, D\u00e1vila R, et al. Perspectives of healthcare professionals on training for quantitative G6PD testing during implementation of tafenoquine in Brazil (QualiTRuST study). PLoS Negl Trop Dis. 2024;18:e0012197.","journal-title":"PLoS Negl Trop Dis"},{"key":"5636_CR19","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/S1473-3099(24)00074-4","volume":"4","author":"M Brito","year":"2024","unstructured":"Brito M, Rufatto R, Brito-Sousa JD, Murta F, Sampaio V, Balieiro P, et al. Operational effectiveness of tafenoquine and primaquine for the prevention of Plasmodium vivax recurrence in Brazil: a retrospective observational study. Lancet Infect Dis. 2024;4:629\u201338.","journal-title":"Lancet Infect Dis"},{"key":"5636_CR20","doi-asserted-by":"publisher","first-page":"650","DOI":"10.3390\/pathogens12050650","volume":"12","author":"A Sadhewa","year":"2023","unstructured":"Sadhewa A, Cassidy-Seyoum SA, Acharya S, Devine A, Price RN, Mwaura M, et al. A review of the current status of G6PD deficiency testing to guide radical cure treatment for vivax malaria. Pathogens. 2023;12:650.","journal-title":"Pathogens"},{"key":"5636_CR21","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgph.0003476","volume":"4","author":"SA Cassidy-Seyoum","year":"2024","unstructured":"Cassidy-Seyoum SA, Chheng K, Chanpheakdey P, Meershoek A, Hsiang MS, von Seidlein L, et al. Implementation of Glucose-6-Phosphate dehydrogenase (G6PD) testing for Plasmodium vivax case management, a mixed method study from Cambodia. PLoS Glob Public Health. 2024;4:e0003476.","journal-title":"PLoS Glob Public Health"},{"key":"5636_CR22","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1186\/s12936-025-05425-3","volume":"24","author":"SA Cassidy-Seyoum","year":"2025","unstructured":"Cassidy-Seyoum SA, Mwaura M, Chheng K, Kejela M, Korra KG, Wodaj T, et al. Co-design of a routine clinical review to improve the safety of high dose radical cure treatment for Plasmodium vivax malaria: findings from Cambodia and Ethiopia. Malar J. 2025;24:171.","journal-title":"Malar J"},{"key":"5636_CR23","unstructured":"Asia Pacific Malaria Elimination Network (APMEN). A new era in malaria elimination unfolds in Pakistan. 2023. Available from: https:\/\/apmen.org\/blog\/new-era-malaria-elimination-unfolds-pakistan."},{"key":"5636_CR24","unstructured":"Global Fund approves emergency funding to help maintain essential health services in Pakistan. 2022 Press release Global Fund. Avaialble from: https:\/\/www.theglobalfund.org\/en\/news\/2022\/2022-09-20-global-fund-approves-emergency-funding-to-maintain-essential-health-services-in-pakistan\/."},{"key":"5636_CR25","unstructured":"The Global Fund to Fight AIDS, Tuberculosis and Malaria. 2023 Results Report. Available from: https:\/\/archive.theglobalfund.org\/media\/13263\/archive_2023-results-report_report_en.pdf"},{"key":"5636_CR26","doi-asserted-by":"publisher","DOI":"10.1136\/bmjgh-2018-001013","volume":"4","author":"SA Zaidi","year":"2019","unstructured":"Zaidi SA, Bigdeli M, Langlois EV, Riaz A, Orr DW, Idrees N, et al. Health systems changes after decentralisation: progress, challenges and dynamics in Pakistan. BMJ Glob Health. 2019;4:e001013.","journal-title":"BMJ Glob Health"},{"key":"5636_CR27","unstructured":"Association for Community Development (ACD). Malaria. Available from: https:\/\/backup.acd.org.pk\/health-projects\/malaria\/"},{"key":"5636_CR28","volume":"2013","author":"M Malik","year":"2013","unstructured":"Malik M, Hassali MA, Shafie AA, Hussain A. Why hospital pharmacists have failed to manage antimalarial drugs stock-outs in Pakistan? A qualitative insight. Malar Res Treat. 2013;2013:342843.","journal-title":"Malar Res Treat"},{"key":"5636_CR29","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1590\/S1984-82502013000200014","volume":"49","author":"M Malik","year":"2013","unstructured":"Malik M, Hassali MA, Shafie AA, Hussain A. A qualitative study exploring perspectives towards rational use of medicines in Pakistan\u2019s Malaria Control Program (MCP). Braz J Pharm Sci. 2013;49:321\u20138.","journal-title":"Braz J Pharm Sci"},{"key":"5636_CR30","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1186\/s12936-017-1901-1","volume":"16","author":"A Bennett","year":"2017","unstructured":"Bennett A, Avance\u00f1a AJ, Cotter C, Roberts K, Gosling R. Engaging the private sector in malaria surveillance: a review of strategies and recommendations for elimination settings. Malar J. 2017;16:252.","journal-title":"Malar J"}],"container-title":["Malaria Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12936-025-05636-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12936-025-05636-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12936-025-05636-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T15:21:06Z","timestamp":1762874466000},"score":1,"resource":{"primary":{"URL":"https:\/\/malariajournal.biomedcentral.com\/articles\/10.1186\/s12936-025-05636-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,11]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["5636"],"URL":"https:\/\/doi.org\/10.1186\/s12936-025-05636-8","relation":{},"ISSN":["1475-2875"],"issn-type":[{"value":"1475-2875","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,11]]},"assertion":[{"value":"2 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"MM, ZH, NH, and AH are members of the Malaria Technical Working Group in Pakistan. RNP participated in the World Health Organization Guideline Development Group on near-patient G6PD tests to support safe and effective P. vivax anti-relapse treatment.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interest"}}],"article-number":"393"}}